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i.org/1increased risk of cardiovascular morbidity and mortality. Left ventricular (LV) global
longitudinal strain (GLS) is a measure of LV systolic function associated with prognosis in
the general population. However, little is known about the association between LV GLS and
survival in patients with CKD. The aim of the present study was to investigate the prog-
nostic implications of LV GLS in predialysis and dialysis patients specifically. LV GLS was
measured in a retrospective cohort of predialysis and dialysis patients (CKD stage 3b to 5)
who underwent clinically indicated echocardiography between 2004 and 2015. Patients
were divided into 4 groups according to quartiles of LV GLS: first quartile (LV GLS
£10.6%, worst function), second quartile (LV GLS 10.7% to 15.1%), third quartile (LV GLS
15.2% to 17.8%), and fourth quartile (LV GLS ‡17.9%, best function). The primary end
point was all-cause mortality. Of 304 patients (62 – 14 years, 66% male), 65% were in
predialysis and 35% in dialysis. During a median follow-up of 29 months (interquartile
range 16 to 58 months), 34% of patients underwent renal transplantation and 36% died.
Patients with LV GLS £10.6% showed significantly worse prognosis compared with the
other groups (log-rank test, p <0.001). LV GLS £10.6% was significantly associated with
increased risk of all-cause mortality (hazard ratio 2.18, 95% CI 1.17 to 4.06, p [ 0.014)
after correcting for age, gender, albumin levels, atrial fibrillation, and renal transplantation.
In conclusion, in predialysis and dialysis patients, severely impaired LV GLS is indepen-
dently associated with an increased risk of mortality.  2017 The Author(s). Published by
Elsevier Inc. This is an open access article under the CC BY license (http://
creativecommons.org/licenses/by/4.0/). (Am J Cardiol 2017;120:500e504)Chronic kidney disease (CKD) is a worldwide growing
epidemic associated with an increased risk of cardiovascular
morbidity and mortality.1e4 Heart failure is particularly
frequent in patients with CKD.2 Pressure and volume
overload and nonhemodynamic factors associated with
CKD induce left ventricular (LV) hypertrophy, reduce
capillary density, and increase myocardial fibrosis that lead
to LV diastolic and systolic dysfunction.5 These processes
have been proposed as important determinants of increased
mortality in this population.5 LV global longitudinal strain
(GLS) assessed with 2-dimensional speckle-tracking echo-
cardiography is a marker of LV systolic function and has
been shown to correlate with the extent of myocardial
fibrosis.6,7 The incremental prognostic value of LV GLS
over conventional echocardiographic parameters of LV
systolic function such as LV ejection fraction has been
demonstrated in patients with various cardiovascular dis-
eases (ischemic heart disease, valvular heart disease, and
heart failure).8 However, little is known about the associa-
tion between LV GLS and prognosis in patients with CKD.f Cardiology and bDepartment of Internal Medicine,
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0.1016/j.amjcard.2017.04.054Accordingly, the aim of the present study was to investigate
the prognostic implications of LV GLS in predialysis and
dialysis patients specifically.
Methods
From a departmental database of predialysis and dialysis
patients, those who were clinically referred for transthoracic
echocardiography at the Leiden University Medical Center
between 2004 and 2015 were identified and included in this
retrospective study. Patients were diagnosed with CKD stage
3b to 5 according to the classification of the Kidney Disease:
Improving Global Outcomes 2012 Clinical Practice Guide-
line for the Evaluation and Management of CKD.9 Patients
younger than 18 years, with limited echocardiographic ex-
amination or with inadequate image quality for off-line
analysis, were excluded. Clinical data were collected
through review of the electronic medical records (HiX;
ChipSoft, Amsterdam, the Netherlands) and the departmental
cardiology information system (EPD-vision; Leiden Univer-
sity Medical Center, Leiden, the Netherlands) and retro-
spectively analyzed. Patients were followed up for the
occurrence of all-cause mortality through case record review
and the national death registry. The occurrence of renal
transplantation during follow-up was registered through case
record review. The institutional review board approved this
retrospective analysis of clinically acquired data.
Baseline clinical variables included demographic pa-
rameters, cardiovascular risk factors, medication use, andccess article www.ajconline.org
Table 1
Characteristics of predialysis and dialysis patients
Variable N¼304
Clinical characteristics:





Dialysis type (haemodialysis)* 82 (77%)
Dialysis vintage (days)* 157 (53-357)
Renal transplantation future 104 (34%)
Heart rate (beats per minute) 73  15
Systolic blood pressure (mmHg) 136  22
Diastolic blood pressure (mmHg) 77  12
Body mass index (kg/m2) 25  5
NYHA class III-IV 29 (10%)
Smoker 184 (63%)
Diabetes mellitus 90 (30%)
Hypertension 252 (83%)
Hypercholesterolemia 120 (39%)
Previous myocardial infarction 71 (23%)
Previous CABG/PCI 76 (25%)
Peripheral artery disease 52 (17%)
Atrial fibrillation 63 (21%)
Medications:
Diuretics 198 (67%)
ACE inhibitor/ARB 184 (62%)
Beta-blocker 182 (61%)
Calcium antagonist 119 (40%)
Statin 181 (61%)
Antiplatelet 99 (33%)
Oral anticoagulation 83 (28%)
Nitrates 34 (11%)
Laboratory results:
Residual renal function (ml/min)* 5.3 (2.2-8.9)
eGFR CKD-EPI (mL/min/1.73m2)† 18  7
Creatinine (umol/L)† 312  116
Urea (mmol/L) 22  7
Corrected calcium (mmol/L) 2.2  0.1
Phosphate (mmol/L) 1.4  0.4
Parathyroid hormone (pmol/L) 16 (8-25)
Albumin (g/L) 41  6
Glucose (mmol/L) 6  3
LDL-cholesterol (mmol/L) 2.4  1.1
Hemoglobin (mmol/L) 7.2  1.0
Continuous data are presented as mean  SD or median (interquartile
range). Categorical data are presented as numbers and percentages.
ACE ¼ angiotensin-converting enzyme; ARB ¼ angiotensin receptor
blocker; CABG ¼ coronary artery bypass graft; CKD-EPI ¼ chronic
kidney disease epidemiology collaboration; eGFR ¼ estimated glomerular
filtration rate; LDL ¼ low-density lipoprotein; NYHA ¼ New York Heart
Association; PCI ¼ percutaneous coronary intervention.
* Measured only in dialysis patients.
† Measured only in predialysis patients.
Miscellaneous/LV GLS in Predialysis and Dialysis 501laboratory results. Estimated glomerular filtration rate was
calculated by the CKD Epidemiology Collaboration (CKD-
EPI) equation.9 Residual renal function was calculated by
the creatinine clearance using the concentration of creatinine
in a 24-hour urine specimen and the predialysis plasma
creatinine concentration.10
Patients were imaged in the left lateral decubitus position
using commercially available systems (Vivid 7 or E9; Gen-
eral Electric Vingmed, Milwaukee, Wisconsin) equipped
with 3.5-MHz or M5S transducers. The echocardiographic
data were digitally stored in cine loop format for off-line
analysis (EchoPac 112.0.1; GE Medical Systems, Horten,
Norway). Linear dimensions of the left ventricle were
measured on M-mode recordings from the parasternal long-
axis view.11 From the apical 4- and 2-chamber views, the
LV end-diastolic and end-systolic volumes were measured
according to the biplane Simpson’s method, and LV ejection
fraction was derived.11 Left atrial volume was measured in
the apical 4-chamber view using the disk summation tech-
nique and was indexed for body surface area. Right ven-
tricular function was assessed by measuring the tricuspid
annular plane systolic excursion on the focused apical 4-
chamber view of the right ventricle applying anatomical M-
mode.11 Mitral regurgitation severity was graded semi-
quantitatively by measuring the width of the vena contracta
from color Doppler data.12 Pulsed wave Doppler recordings
of the mitral inflow were used to measure peak E (early
diastolic) and A (late diastolic) wave velocities. LV relaxa-
tion was assessed with color-coded tissue Doppler imaging
measuring the lateral E0 wave velocity of the mitral annulus in
the apical 4-chamber view, and the E/E0 ratio was derived as a
measure of LV filling pressures.13 LV GLS was measured
using 2-dimensional speckle-tracking echocardiography on
standard routine grayscale images of apical 4-, 2-chamber
and long-axis views.14 Conventionally, LV GLS is presented
as negative values because it indicates the shortening of the
myocardium relative to the original length.14 However, the
magnitude (absolute value) of LV GLS is presented in this
analysis.
Categorical variables were presented as numbers and
percentages. Continuous variables with a normal distribu-
tion were presented as the mean  SD and those without a
normal distribution were presented as the median and
interquartile range. Univariate Cox proportional hazard
analysis was performed to identify the demographic, clin-
ical, and echocardiographic variables associated with all-
cause mortality. Multivariate survival analysis using Cox
proportional hazard model was used to determine the in-
dependent association between LV GLS and all-cause
mortality. LV GLS and LV ejection fraction were not
included in the same model to avoid multicollinearity. The
occurrence of renal transplantation during follow-up was
introduced as a time-dependent covariate. Patients were
divided into 4 groups according to quartiles of LV GLS.
Cumulative event-free survival rates from the time of
echocardiography were calculated using the Kaplan-Meier
method and compared across the quartiles of LV GLS. All
statistical tests were 2 sided and a p-value of <0.05 was
considered statistically significant. Statistical analyses were
performed using the SPSS software, version 20.0 (IBM
Corp, Armonk, New York).Results
A total of 304 patients (66%men, mean age 62 14 years)
were included. Tables 1 and 2 summarize the clinical and
echocardiographic characteristics of the overall patient pop-
ulation. During a median follow-up duration of 29 months
(interquartile range 16 to 58 months), 104 (34%) patients
underwent renal transplantation and 108 (36%) patients died.
Table 2
Echocardiographic characteristics of predialysis and dialysis patients
Variable N¼304
Ventricular septum width (mm) 11  2
Posterior wall width (mm) 10  2
Left ventricular end-diastolic diameter (mm) 53  9
Left ventricular end-systolic diameter (mm) 36  11
Left ventricular end-diastolic volume (ml) 112  53
Left ventricular mass index (gr/m2) 114  36
Left ventricular end-systolic volume (ml) 54  45
Left ventricular ejection fraction (%) 56  16
Left atrial volume index (mL/m2) 29  15
TAPSE (mm) 18  5
Moderate/severe mitral regurgitation 45 (15%)
Peak E-wave velocity (cm/s) 78  31
Peak A-wave velocity (cm/s) 80  26
Lateral E0 (cm/s) 6  3
Lateral E/E0 12 (8-19)
Left ventricular global longitudinal strain (%) 14  5
Continuous data are presented as mean  SD or median (interquartile
range). Categorical data are presented as numbers and percentages.
TAPSE ¼ tricuspid annular plane systolic excursion.
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LV ejection fraction were significantly associated with all-
cause mortality together with age, male gender, albumin
levels, atrial fibrillation, and renal transplantation. LV GLS
(hazard ratio [HR] 0.96, 95%CI 0.92 to 0.998; p¼ 0.041) and
LV ejection fraction (HR 0.99, 95% CI 0.97 to 0.997;
p ¼ 0.019) were independently associated with all-cause
mortality after correcting for age, male gender, albumin
levels, atrial fibrillation, and renal transplantation.
Patients were divided into 4 groups according to quartiles
of LV GLS: first quartile (LV GLS 10.6%, worst func-
tion), second quartile (LV GLS 10.7% to 15.1%), third
quartile (LV GLS 15.2% to 17.8%), and fourth quartile (LV
GLS 17.9%, best function). Kaplan-Meier curves of the
cumulative event-free survival for the different quartiles of
LV GLS are presented in Figure 1. Patients with LV GLS
10.6% (most impaired LV systolic function) showed
significantly worse prognosis compared with the other
groups (log-rank chi-square ¼ 31.17, p <0.001). Impor-
tantly, patients within the lowest LV GLS quartile (LV GLS
10.6%) were less frequently recipients of renal trans-
plantation (8% compared with 32% in patients with LV
GLS 10.7% to 15.1%, 49% in patients with LV GLS 15.2%
to 17.8%, and 47% in patients within the highest LV GLS
quartile 17.9%). On multivariate analysis, LV GLS
10.6% was independently associated with increased risk
of all-cause mortality after correcting for age, gender, al-
bumin levels, atrial fibrillation, and renal transplantation as
time-dependent covariate (Table 3).
Discussion
CKD is associated with structural and functional LV
remodeling as a consequence of pressure and volume over-
load and nonhemodynamic factors.5 Pressure overload is the
result of chronic hypertension and vascular stiffness, whereas
anemia, arteriovenous fistulas, and sodium and water reten-
tion lead to volume overload.15 To keep LV wall stress close
to normal, the left ventricle responds to pressure and volumeoverload with hypertrophy and dilatation.15 As LV hyper-
trophy progresses, the interstitial space also increases with
accumulation of collagen (interstitial or replacement fibrosis)
potentially causing a reduction in contractility. In addition,
LV hypertrophy increases the myocardial oxygen demand,
which causes myocardial hypoperfusion, cardiomyocyte
loss, and further interstitial fibrosis.15,16 Furthermore, non-
hemodynamic factors associated with CKD such as inap-
propriate renin-angiotensin-aldosterone system activation,
oxidative stress, inflammation, and stimulation of prohyper-
trophic and profibrogenic factors also contribute to LV
remodeling.5,15 These structural changes cause impaired LV
contractility, which can be detected with LV GLS. Several
studies have demonstrated the correlation between LV GLS
and the extent of myocardial fibrosis.6,7 In a recent study,
Kramann et al7 showed that LV strain parameters were
significantly associated with the grade of myocardial fibrosis
in rat models with uremic cardiomyopathy. The larger the
extent of myocardial fibrosis, the more impaired the value of
LV GLS. In addition, it has been shown that LV GLS is a
more sensitive marker of LV systolic dysfunction than LV
ejection fraction.17 Patients with LV hypertrophy and pre-
served LV ejection fraction may show impaired LV GLS in
various clinical scenarios indicating that LV GLS better re-
flects the true damage of the LV myocardium compared with
LV ejection fraction.18 In the present study, the mean LV
ejection fraction was >50% in most predialysis and dialysis
patients. However, mean LV GLS was significantly reduced
suggesting that the LV contractility is significantly reduced
probably because of ongoing LV remodeling with increased
fibrosis formation.
The prognostic value of LV GLS has been demon-
strated in several clinical scenarios, including patients with
preserved LV ejection fraction.8,19,20 However, the evi-
dence correlating LV GLS and prognosis in patients with
CKD is limited.7,21,22 In a recent study, including 171
dialysis patients, LV GLS was independently associated
with all-cause mortality (HR 1.10, 95% CI 1.03 to 1.17;
p <0.01).7 In addition, in 447 patients with a wide range of
estimated GFR, LV GLS was independently associated
with all-cause mortality (HR 1.08, 95% CI 1.01 to 1.15;
p ¼ 0.03).21 Similar results were observed in a study
including 183 patients with stage 4 and 5 CKD, where LV
GLS was independently associated with all-cause mortal-
ity (HR 1.09, 95% CI 1.02 to 1.16; p ¼ 0.01).22 The
present study, with the largest cohort of predialysis and
dialysis patients so far, demonstrates that patients within
the lowest quartile of LV GLS showed worse prognosis
compared with the other groups, and LV GLS 10.6%
was associated with twofold increased risk of all-cause
mortality after correcting for renal transplantation. This
is clinically relevant because renal transplantation is
considered as a life-saving treatment in these patients and
proper selection of patients receiving a renal transplant is
crucial to optimize the results of this therapy. Whether LV
GLS improves after renal transplantation has not been
evaluated.
Several limitations should be acknowledged. First, this
was an observational, retrospective study. In addition, only
predialysis and dialysis patients from the departmental
database were included in the present study, after having a
Figure 1. Kaplan-Meier curves of the cumulative event-free survival according to the LV GLS quartile. The cumulative survival rates were compared between
the different quartiles of LV GLS.
Table 3






Renal transplantation 0.08 (0.04-0.15) <0.001 0.31 (0.15-0.66) 0.002
Age (years) 1.07 (1.05-1.09) <0.001 1.05 (1.03-1.07) <0.001
Men 1.26 (0.83-1.90) 0.279 1.02 (0.67-1.57) 0.917
Albumin (g/L) 0.90 (0.87-0.93) <0.001 0.89 (0.86-0.92) <0.001
Atrial fibrillation 2.06 (1.35-3.13) 0.001 1.15 (0.73-1.80) 0.542
LV GLS (versus 17.9%)
15.2-17.8% 1.41 (0.71-2.79) 0.323 1.80 (0.91-3.59) 0.094
10.7-15.1% 2.12 (1.12-4.01) 0.021 1.38 (0.72-2.64) 0.328
10.6% 4.00 (2.19-7.31) <0.001 2.18 (1.17-4.06) 0.014
CI ¼ confidence interval; GLS ¼ global longitudinal strain; HR ¼ hazard ratio; LV ¼ left ventricular.
Miscellaneous/LV GLS in Predialysis and Dialysis 503clinically indicated echocardiography, introducing a poten-
tial selection bias. Furthermore, echocardiography was
performed after dialysis therapy, where LV GLS may have
been affected by changes in loading conditions.
In predialysis and dialysis patients, severely impaired LV
GLS was independently associated with worse prognosis,
even after correction for renal transplantation.Disclosures
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